The purpose of the study is to find out the daytime and nighttime effects of XYWAV on symptoms and daily functioning and on sleep quality and quantity.
Study is for approximately 10 to 21 weeks.
Criteria:
18 years to 75 years of age
Has a primary diagnosis of Idiopathic Hypersomnia meeting ICSD-3 criteria or narcoplesy (Type 1 or Type 2) meeting ICSD-3 or DSM-V criteria.